Kim Chi, MD

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

Kim Chi, MD, discusses future research directions with PARP inhibitors in metastatic prostate cancer.

Kim Chi, MD, discusses the design of the phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Kim Chi, MD, discusses prostate cancer biomarker enrichment and treatment selection study.

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.